14 results about "Zinc binding" patented technology

The invention discloses a preparation method of a crocodile hydrolyzed protein zinc skin care product, and relates to the technical field of skin care. The method comprises the following steps: step a, pretreating raw materials: taking fresh crocodile meat and bones, cleaning, mechanically crushing until the particle size is less than 5mm, and adding water according to the ratio of 1: (3-5) to prepare homogenate; step b, performing three-step enzymolysis, namely performing enzymolysis by adopting alkaline protease, flavourzyme and zinc chelating enzyme in sequence; according to the constructed technology of three-step enzymolysis and three-stage membrane separation, accurate preparation of crocodile protein zinc is achieved, and the zinc chelating rate is increased to 90% or above through the gradient effect of alkaline protease, flavourzyme and zinc chelating enzyme and directional release of zinc binding sites and is remarkably higher than that of a traditional single-enzyme hydrolysis technology; meanwhile, a combined purification technology of a ceramic membrane, an ultrafiltration membrane and a nanofiltration membrane is adopted to replace chemical precipitation and organic solvent extraction, so that the completeness of active ingredients is reserved, the risk of environmental pollution is reduced, and the method conforms to the green manufacturing trend of food industry.

The invention provides a method of treating cancer in a subject in need thereof, comprising administering to the subject:(a) a compound of Formula I:or a pharmaceutically acceptable salt thereof, wherein R is hydrogen or an acyl group; and(b) a PD-1 signaling inhibitor; wherein the compound of Formula I or pharmaceutically acceptable salt thereof and the PD-1 signaling inhibitor are administered in amounts which in combination are therapeutically effective. The invention further provides a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, a PD-1 signaling inhibitor and a pharmaceutically acceptable carrier or excipient.

The present invention provides a method for treating cancer in a subject in need thereof, the method comprising administering to the subject: (a) a compound of formula I or a pharmaceutically acceptable salt thereof: wherein R is hydrogen or acyl; and (b) a PD-1 signal transduction inhibitor; wherein the compound of formula I or a pharmaceutically acceptable salt thereof and the PD-1 signal transduction inhibitor are administered in a therapeutically effective combined amount. The present invention also provides a pharmaceutical composition, which comprises a compound of formula I or a pharmaceutically acceptable salt thereof, a PD-1 signal transduction inhibitor, and a pharmaceutically acceptable carrier or excipient.

The instant application relates to deazapurines, thienopyrimidines and furopyrimidines with zinc-binding moiety based derivatives and their use in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.

The preparation method of the zinc-chelated salmon fishbone phosphopeptide comprises the following steps: adding water into salmon fishbone powder, homogenizing, centrifuging and drying to obtain salmon fishbone crude protein, hydrolyzing by using a compound enzyme, and filtering to obtain the zinc-chelated salmon fishbone phosphopeptide. Performing enzyme deactivation and centrifugation to obtain a salmon fish bone peptide solution, and performing dialysis and freeze drying to obtain salmon fish bone peptide freeze-dried powder; the preparation method comprises the following steps: compounding salmon fishbone peptide freeze-dried powder and sodium tripolyphosphate to prepare salmon fishbone phosphopeptide freeze-dried powder, dissolving the salmon fishbone phosphopeptide freeze-dried powder in water, carrying out chelation reaction on the salmon fishbone phosphopeptide freeze-dried powder and a zinc source to obtain a compound solution, and carrying out ethanol precipitation, centrifugal separation and drying treatment to obtain the zinc-chelated salmon fishbone phosphopeptide. The zinc-chelated salmon fishbone phosphopeptide prepared by the chelating reaction of the salmon fishbone compound enzyme phosphopeptide and zinc ions is high in antioxidant activity and strong in zinc binding capacity, the absorptivity and bioavailability of the zinc element are effectively improved, and the taste of the product is optimized.

There is provided inter alia an aqueous liquid pharmaceutical formulation comprising (i) an insulin compound, (ii) ionic zinc, (iii) a zinc binding species at a concentration of 1 mM or more selected from species having a log K with respect to zinc ion binding in the range 4.5-12.3 at 25° C., and (iv) a non-ionic surfactant which is an alkyl glycoside; and wherein the formulation is substantially free of EDTA and any other zinc binding species having a log K with respect to zinc ion binding of more than 12.3 at 25° C.

The present invention relates to a novel zinc-binding dehydrogenase variant and a method of producing an L-aromatic amino acid using the same. The zinc-binding dehydrogenase variant is obtained by substituting one or more amino acids in the amino acid sequence constituting zinc-binding dehydrogenase to change the enzymatic activity of the zinc-binding dehydrogenase, and a recombinant microorganism comprising the variant is capable of efficiently producing an L-aromatic amino acid.

The invention discloses an inorganic-organic mixed acid etched zinc negative electrode material and a preparation method and application thereof, and belongs to the technical field of aqueous zinc ion batteries. The invention aims to solve the problem that the service life of the battery is shortened due to zinc dendrite growth, corrosion and hydrogen evolution in the practical application of the current aqueous zinc ion battery. The mixed acid of hydrochloric acid and citric acid is used for etching commercial zinc foil to obtain the zinc negative electrode etched by inorganic / organic mixed acid, the zinc negative electrode is applied to the aqueous zinc ion battery negative electrode, the three-dimensional structure of the zinc negative electrode can uniformly distribute an electric field, and the high specific surface area can reduce the local current density, so that zinc ions are more uniformly distributed in the deposition / stripping process; and dendritic crystal formation is reduced. And meanwhile, a zinc citrate layer rich in zinc binding sites is generated on the surface in situ, so that the nucleation barrier of zinc ions can be reduced, uniform nucleation is promoted, and under the dual action of the three-dimensional structure and the zinc-loving layer, the generation of zinc dendrites is further inhibited, and the electrochemical performance of the zinc ion battery is effectively improved.

To provide a metal chelate compound having high binding capability to zinc as an antimycotic drug.SOLUTION: An antimycotic drug comprises, as an active ingredient, a polyamine compound represented by formula (1) or a salt thereof. (In the formula, R1, R2, R3, R4, R5, and R6 are each independently hydrogen, halogen, C1-C5 alkyl, C1-C5 haloalkyl, or C1-C5 haloalkoxy).SELECTED DRAWING: Figure 1

The invention discloses electroplating liquid for preparing an aqueous zinc ion battery negative electrode and application of the electroplating liquid, and relates to the technical field of aqueous zinc ion battery negative electrodes. Aiming at the problems of dendritic crystal growth and the like of a zinc negative electrode in an aqueous zinc ion battery, the electroplating liquid is optimized by introducing specific additives, namely L-xylose (L-Xylose) and ribose (Ribose), and the distribution and thickness of a zinc coating on the surface of a copper foil can be adjusted by changing current and electroplating time. According to the zinc negative electrode material prepared by using the electroplating solution, due to the unique petal-shaped three-dimensional structure, more zinc ion deposition sites can be provided, the specific surface area of an electrode can be increased, and the uniformity and reversibility of zinc deposition are remarkably improved. The binding energy of copper and zinc in the copper-zinc compound is high, agglomeration of zinc atoms can be reduced, the petal-shaped copper-zinc compound can reconstruct a solvation structure of Zn < 2 + >, a desolvation energy barrier is reduced, an electrolyte interface double-electrode-layer structure is optimized, and zinc dendrite growth is inhibited, so that the efficiency of the battery is improved, and the service life of the battery is prolonged.

The present invention relates to a novel zinc-binding dehydrogenase variant and a method of producing an L-aromatic amino acid using the same. The zinc-binding dehydrogenase variant is obtained by substituting one or more amino acids in the amino acid sequence constituting zinc-binding dehydrogenase to change the enzymatic activity of the zinc-binding dehydrogenase, and a recombinant microorganism comprising the variant is capable of efficiently producing an L-aromatic amino acid.

The present invention relates to a Vitis sp. plant or part thereof having a reduced level of flower sex polypeptide (FSL) activity compared to a corresponding wild-type Vitis sp. plant or part thereof having an FSL locus genotype that confers a hermaphrodite flower phenotype, wherein said Vitis sp. plant or part thereof comprises an FSL locus comprising a polynucleotide sequence encoding the FSL polypeptide, and wherein the polynucleotide sequence comprises a genetic modification in the region encoding a plant domain with an AT₂-rich zinc-binding sequence (PLATZ) of the FSL polynucleotide in relation to a corresponding polynucleotide sequence of a wild-type Vitis sp. FSL locus allele that confers a hermaphrodite flower phenotype when expressed, whereby the genetic modification causes a male reproductive part of a flower in the Vitis sp. plant to be expressed.or part of it is not functional.

The invention provides a method of treating cancer in a subject in need thereof, comprising administering to the subject: (a) a compound of Formula I: (I) or a pharmaceutically acceptable salt there- of, wherein R is hydrogen or an acyl group; and (b) a PD-1 signaling inhibitor, wherein the compound of Formula I or pharmaceutically ac- ceptable salt thereof and the PD-1 signaling inhibitor are administered in amounts which in combination are therapeutically effective. The invention further provides a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, a PD-1 signaling inhibitor and a pharmaceutically acceptable carrier or excipient.

The invention belongs to the field of magnesium alloy electroplating, and discloses a zinc stripping solution for dipping a magnesium alloy in bright zinc and a secondary zinc dipping process. The zinc removing solution for soaking the magnesium alloy in the bright zinc is prepared from a strong acid solution and a fluoride solution, the strong acid solution is hydrochloric acid or nitric acid or sulfuric acid, and the fluoride solution is a potassium fluoride or sodium fluoride or ammonium bifluoride solution; the invention further provides a magnesium alloy secondary zinc immersion process. In the zinc stripping process, fluorine ions and a magnesium matrix react to form an MgF2 passive film, so that the over-corrosion problem is not prone to occurring when a primary zinc dipping layer is dissolved by acid, and meanwhile, the acid has a certain dissolution effect on MgF2, so that the magnesium matrix has a certain polishing effect during zinc stripping; the zinc-removed magnesium alloy which is protected by MgF2 with a certain thickness, high in flatness and good in uniformity can be obtained, and a zinc dipping layer which is high in brightness, good in uniformity, high in compactness, free of zinc dipping leakage and good in binding force can be obtained through a secondary zinc dipping reaction.